In The News

Could Roche’s Alzheimer’s drug failure be Promis Neurosciences gain?

ProMIS tackles Parkinson's and Alzheimer’s diseases

ProMIS Neurosciences (TSX:PMN): Targeting the root cause of Alzheimer’s and other neurodegenerative diseases

Stockhouse - The Key to Unlocking Alzheimers Treatment?

Global Business Report – Interview with Eugene Williams Executive Chairman, ProMIS

ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates

Why Hope Endures For An Alzheimer's Treatment — And Biogen Could Be First

ProMIS Trial Offers Hope For Alzheimer's Patients

Biocentury – Promis Identifies New Beta Amyloid Epitope To Treat AD

As Vtv data nearing in April, Promis AD bid a contender